Elanco Animal Health Inc
SWB:5EA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
Elanco Animal Health Inc
SWB:5EA
|
US |
|
Relmada Therapeutics Inc
F:4E2
|
US |
|
Quantum Computing Inc
NASDAQ:QUBT
|
US |
|
D
|
DXC Technology Co
XETRA:2XT
|
US |
Elanco Animal Health Inc
Elanco Animal Health makes medicines and health products for animals. It sells prescription drugs, vaccines, and parasite control products for pets and farm animals. The company’s main customers are veterinarians, pet owners, livestock producers, and animal health distributors that buy its products and pass them on to end users. Elanco earns money by selling these animal care products through clinics, retailers, distributors, and agricultural channels. Its business is tied to the ongoing need to prevent disease, treat illness, and support animal health rather than one-time purchases of equipment or services. That gives it a recurring, product-based revenue model that depends on pets needing routine care and farms needing healthier animals. What makes Elanco’s role distinct is that it sits between drug research and day-to-day animal care. It develops and markets treatments that help keep companion animals healthy and livestock productive, so it serves both the pet market and the food-animal supply chain. This puts the company in a specialized corner of healthcare where demand is driven by veterinary practice, animal ownership, and the economics of farming.
Elanco Animal Health makes medicines and health products for animals. It sells prescription drugs, vaccines, and parasite control products for pets and farm animals. The company’s main customers are veterinarians, pet owners, livestock producers, and animal health distributors that buy its products and pass them on to end users.
Elanco earns money by selling these animal care products through clinics, retailers, distributors, and agricultural channels. Its business is tied to the ongoing need to prevent disease, treat illness, and support animal health rather than one-time purchases of equipment or services. That gives it a recurring, product-based revenue model that depends on pets needing routine care and farms needing healthier animals.
What makes Elanco’s role distinct is that it sits between drug research and day-to-day animal care. It develops and markets treatments that help keep companion animals healthy and livestock productive, so it serves both the pet market and the food-animal supply chain. This puts the company in a specialized corner of healthcare where demand is driven by veterinary practice, animal ownership, and the economics of farming.
Topline beat: Elanco reported $1.371 billion of revenue, up 15% reported and 10% organic constant currency, and said the quarter beat the high end of guidance on revenue, adjusted EBITDA and adjusted EPS.
Guidance raised: Management raised full-year 2026 outlook for organic constant currency growth to 5% to 7%, adjusted EBITDA to $975 million to $1.005 billion, and adjusted EPS to $1.03 to $1.09.
Innovation driving growth: Zenrelia and Credelio Quattro were the main growth engines, with Zenrelia reaching blockbuster status on a trailing 4-quarter basis and innovation revenue totaling $287 million in Q1.
Margin and leverage: Gross margin fell 40 basis points to 57% because of inflation and inventory cost pressure, but the company still expects stronger margins in the second half and net leverage to improve to 3.0x to 3.2x by year-end.
U.S. Pet rebound: U.S. Pet Health grew 6% in Q1 despite weak weather early in the quarter, then accelerated in March and April; management expects high-single-digit to low-double-digit growth in the back half of the year.
Capital and strategy: Elanco kept its focus on debt paydown, reinvestment in launches, and Elanco Ascend productivity programs, while also saying the FDA asked for more data on Zenrelia and a new study is underway.
